Obesity Today—June 30, 2026

This week’s Obesity update highlights regulatory actions, clinical progress, partnerships, market expansion, and economic burden insights.

In this Newsletter

Dive deeper

🧬 Ascletis ASC35 wins U.S. FDA IND clearance [1] [US • 23 Jun 2026]

https://www.prnewswire.com/apac/news-releases/ascletis-announces-us-fda-ind-clearance-for-phase-i-study-of-once-monthly-subcutaneously-administered-glp-1rgipr-dual-peptide-agonist-asc35-for-the-treatment-of-obesity-302807543.html
Context: Phase 1 will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in 84 adults with obesity or overweight plus comorbidities.
Key point: Ascletis said the U.S. FDA cleared an IND for ASC35 in obesity.
Implication: May influence prescriber choice and payer reviews pending full data.

⚖️ Viking starts Phase 1 for VK3019 amylin program [2] [US • 24 Jun 2026]

https://www.prnewswire.com/news-releases/viking-therapeutics-announces-initiation-of-phase-1-study-to-evaluate-novel-amylin-receptor-agonist-vk3019-in-healthy-adults-302808417.html
Context: VK3019 is an investigational dual amylin and calcitonin receptor agonist being evaluated in healthy adults with BMI ≥30.
Key point: Viking Therapeutics initiated a Phase 1 single ascending dose study of VK3019 for potential weight loss.
Implication: Signals pipeline investment and modality expansion.

💊 Corxel reports positive Phase 2 CX11 obesity data [3] [US • 23 Jun 2026]

https://www.bioworld.com/articles/732050-corxel-vincentages-oral-glp-1-meets-phase-ii-obesity-endpoints?v=preview
Context: The 246-participant trial evaluated once-daily CX11, an oral small molecule GLP-1 receptor agonist, over 36 weeks in adults with obesity or overweight and at least one comorbidity.
Key point: Corxel reported positive U.S. Phase 2 topline results for CX11.
Implication: May influence prescriber choice and payer reviews pending full data.

🧾 Can-Fite gains Japanese patent allowance for Namodenoson [4] [Japan • 26 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/26/3318141/0/en/Can-Fite-Secures-Japanese-Patent-Allowance-for-Namodenoson-s-Anti-Obesity-Technology.html
Context: The company described Namodenoson as an oral A3 adenosine receptor agonist with obesity-related intellectual property in multiple markets.
Key point: Can-Fite said Japan allowed a patent covering A3AR agonists, including Namodenoson, for fat loss and obesity.
Implication: Introduces competition that may affect pricing and formulary access.

🤝 GC Wellbeing licenses RZL-012 rights in Korea [5] [Korea • 26 Jun 2026]

https://www.koreatimes.co.kr/business/companies/20260626/gc-wellbeing-secures-rights-to-obesity-treatment-rzl-012-for-korean-market
Context: The agreement with Raziel Therapeutics was finalized at BIO International Convention 2026 in San Diego.
Key point: GC Wellbeing signed a strategic partnership to secure Korean commercialization rights for RZL-012.
Implication: Signals pipeline investment and modality expansion.

🇦🇺 GlobalData sizes Australia’s obesity economic burden [6] [Australia • 29 Jun 2026]

https://healthcareasiamagazine.com/healthcare/in-focus/obesity-drains-45b-annually-australias-economy
Context: The report linked obesity-related costs to productivity, healthcare, public finances, and workforce participation.
Key point: GlobalData estimated obesity and overweight cost Australia approximately $45 billion annually.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🇨🇳 Novo Nordisk deepens China integration [7] [China • 26 Jun 2026]

https://english.news.cn/20260626/04fdc5a13c0444919604ef4330b64508/c.html
Context: Novo Nordisk cited China’s market scale, launch speed, local partnerships, and innovation ecosystem.
Key point: The company’s CEO said China is becoming increasingly integrated into Novo Nordisk’s global corporate strategy.
Implication: Signals pipeline investment and modality expansion.

💊 Lilly eyes China launch window for orforglipron [8] [China • 24 Jun 2026]

https://www.reuters.com/legal/litigation/china-approval-eli-lilly-glp-1-pill-come-soon-2026-executive-says-2026-06-24/
Context: Lilly submitted a China marketing application for once-daily orforglipron at the end of 2025.
Key point: Eli Lilly said a China launch for orforglipron could occur between late 2026 and early 2027.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 Evaluate forecasts obesity-driven pharma growth [9] [Global • 23 Jun 2026]

https://www.fiercepharma.com/pharma/big-obesity-bets-and-chinas-rise-fuel-potential-2t-2032-drug-sales-evaluate
Context: The report cited China-sourced licensing assets, M&A activity, pricing pressure, and patent cliff risks.
Key point: Evaluate forecast that obesity and inflammatory disease therapies could help lift global pharmaceutical sales above $2 trillion by 2032.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Oral and long-acting obesity candidates remain central to pipeline differentiation.
China is increasingly positioned as both a launch market and a source of biopharma assets.
Amylin, calcitonin, A3AR, and localized adipose-targeting approaches show continued modality expansion.
Economic burden data may strengthen payer and policy interest in prevention and treatment access.
Crowded obesity pipelines raise the bar for tolerability, dosing convenience, and durable outcomes.

📚 View the full Obesity archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What is Ascletis ASC35?

ASC35 is Ascletis’ once-monthly subcutaneous GLP-1R/GIPR dual peptide agonist for obesity. The cleared Phase 1 study will test safety, tolerability, PK, and PD in 84 adults [1].

What is Viking VK3019 designed to do?

VK3019 is an investigational dual amylin and calcitonin receptor agonist. Viking is testing single subcutaneous doses in a Phase 1 SAD study in healthy adults with BMI ≥30 [2].

What did Corxel report for CX11?

Corxel reported positive topline U.S. Phase 2 results for CX11, an oral small molecule GLP-1 receptor agonist. The study enrolled 246 adults and ran for 36 weeks [3].

What does Can-Fite’s Japanese patent cover?

The allowed Japanese patent covers A3 adenosine receptor agonists, including Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders [4].

What did Lilly say about orforglipron in China?

Lilly said China launch timing for once-daily orforglipron could be late 2026 to early 2027, subject to approval timing [8].

Why is Novo Nordisk focused on China?

Novo Nordisk cited China’s market potential, operational speed, local partnerships, and innovation ecosystem as reasons to deepen integration [7].

Entities / Keywords

Ascletis Pharma, ASC35, GLP-1R/GIPR dual peptide agonist, once-monthly obesity therapy
Viking Therapeutics, VK3019, dual amylin and calcitonin receptor agonist, DACRA
Corxel Pharmaceuticals, Vincentage Pharma, CX11, oral GLP-1 receptor agonist
Can-Fite BioPharma, Namodenoson, A3 adenosine receptor, A3AR
GC Wellbeing, Raziel Therapeutics, RZL-012, Korea commercialization rights
GlobalData, Australia obesity burden, productivity costs, healthcare costs
Novo Nordisk, China strategy, Kyinsu, diabetes and obesity market
Eli Lilly, orforglipron, oral GLP-1, China NMPA application
Evaluate, World Preview 2026, obesity drug sales, pharma market forecast